Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 1,140,000 shares, a decrease of 16.8% from the March 31st total of 1,370,000 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.
Separately, Zacks Investment Research raised shares of Eagle Pharmaceuticals from a “sell” rating to a “buy” rating and set a $48.00 target price on the stock in a research note on Monday, March 8th.
Hedge funds have recently modified their holdings of the stock. Lazard Asset Management LLC raised its stake in Eagle Pharmaceuticals by 1,208.9% in the fourth quarter. Lazard Asset Management LLC now owns 1,610 shares of the specialty pharmaceutical company’s stock worth $74,000 after buying an additional 1,487 shares in the last quarter. ProShare Advisors LLC purchased a new stake in shares of Eagle Pharmaceuticals during the 4th quarter worth $211,000. Oregon Public Employees Retirement Fund boosted its position in Eagle Pharmaceuticals by 17.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,783 shares of the specialty pharmaceutical company’s stock valued at $223,000 after purchasing an additional 724 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Eagle Pharmaceuticals in the third quarter valued at about $249,000. Finally, Nisa Investment Advisors LLC raised its holdings in Eagle Pharmaceuticals by 130.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,472 shares of the specialty pharmaceutical company’s stock worth $255,000 after purchasing an additional 3,098 shares in the last quarter. 95.12% of the stock is currently owned by institutional investors.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings results on Monday, March 1st. The specialty pharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $2.38. The business had revenue of $49.92 million for the quarter, compared to the consensus estimate of $50.08 million. Eagle Pharmaceuticals had a return on equity of 8.50% and a net margin of 2.65%. On average, equities analysts forecast that Eagle Pharmaceuticals will post -1.07 earnings per share for the current year.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
Further Reading: CD Ladder
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.